Table 1.
Association between MAPK pathway-altered genes with best response by RECIST v1.1 in binimetinib-treated patients.
| Overall (n = 135) | CR/PR (n = 37; RR) | SD/PD (n = 98) | ||
|---|---|---|---|---|
| Alteration Identified | n (% altered) | n (%) | n | P a |
| KRAS: | 0.004 | |||
| ALT | 45 (33%) | 20 (44%) | 25 | |
| WT | 90 (67%) | 17 (19%) | 73 | |
| NRAS: | 0.2 | |||
| ALT | 11 (8%) | 5 (46%) | 6 | |
| WT | 124 (92%) | 32(26%) | 92 | |
| BRAFV600E: | >0.9 | |||
| ALT | 8 (6%) | 2 (25%) | 6 | |
| WT | 127 (94%) | 35(28%) | 92 | |
| RAF1: | 0.5 | |||
| ALT | 2 (1.5%) | 1 (50%) | 1 | |
| WT | 133 (99%) | 36 (27%) | 97 | |
| NF1: | >0.9 | |||
| ALT | 7 (5%) | 2 (29%) | 5 | |
| WT | 128 (95%) | 35 (27%) | 93 | |
| MAPK Pathway: | <0.001 | |||
| ALT | 68 (50%) | 28 (41%) | 40 | |
| WT | 67 (50%) | 9 (13%) | 58 |
Abbreviations: ALT, altered; RECIST, Response Evaluation Criteria in Solid Tumors; RR, response rate.
a P values calculated with the Fisher exact test.